Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor
Oncolytic viruses combined with immunotherapy offer significant potential in tumor therapy.In this study, we engineered a further attenuated pseudorabies virus (PRV) vaccine strain that incorporates a PD-L1 inhibitor and demonstrated its promise as an oncolytic virus in tumor therapy.We first showed that the naturally attenuated PRV vaccine strain